Vibratab

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vibratab

Quick Facts

Property Description
Active ingredient Doxycycline (Doxycycline hyclate)
Form Tablet (Oral formulation)
Pharmacological class Tetracycline antibiotic
Common use Anti-infective agent (Systemic)
Origin Semi-synthetic

What Type of Medicine is Vibratab (Doxycycline)?

Vibratab is a prescription-only medicine containing the active ingredient Doxycycline, which is classified as a broad-spectrum anti-infective agent. This drug belongs specifically to the Tetracycline antibiotic pharmacological class. As a systemic treatment, its primary function is to work throughout the body to address various microbial diseases. Doxycycline is highly effective against a variety of bacteria and protozoa, confirming its extensive utility as an anti-microbial agent. Vibratab is presented in the form of a solid dosage form tablet intended for oral administration, a characteristic that supports its long-standing clinical recognition as a foundational oral antibiotic.


Composition, Origin, and Form

The core component of Vibratab is Doxycycline, most commonly utilized in the form of Doxycycline hyclate, an established chemical salt that ensures stability and proper absorption. The active compound is categorized as a semi-synthetic derivative, meaning it is chemically modified from a naturally occurring core structure to enhance its efficacy and pharmacological profile. Vibratab is a single-ingredient product, and the tablets consist of the active compound combined with solid excipients. Its composition is pharmacologically confirmed to ensure consistent systemic availability, making it a reliable choice when treating systemic bacterial infections, such as those that might affect skin or respiratory function.


How Does Vibratab Generally Function?

Vibratab generally functions by disrupting the ability of bacteria to grow and multiply within the body, an action known as bacteriostasis. The Doxycycline molecule achieves this by interfering directly with bacterial protein synthesis, specifically by binding to the 30S ribosomal subunit inside the target cells. This mechanism of action, which has been widely studied across multiple decades, allows Doxycycline to effectively prevent the bacteria from reproducing and spreading. This interference effectively halts the bacteria's reproductive cycle, allowing the host's natural immune system to successfully contain and eliminate the underlying microbial disease, which defines its general therapeutic purpose as a reliable anti-infective agent.

What side effects are possible with Vibratab?

Vibratab (doxycycline) is generally well-tolerated, but like all medications, it can cause side effects. Most side effects are minor, but some can be serious.

Common Side Effects

Commonly reported side effects often involve the gastrointestinal system and skin. These may include:

  • Nausea, vomiting, or diarrhea
  • Loss of appetite
  • Skin rash or hives
  • Increased sensitivity of the skin to sunlight (photosensitivity), which can lead to severe sunburn. Patients should minimize sun exposure, wear protective clothing, and use sunscreen.
  • Vaginal yeast infection (candidiasis) or oral thrush due to the overgrowth of non-susceptible organisms.

Serious Side Effects and When to Seek Medical Attention

Contact a healthcare professional immediately if you experience any signs of a serious reaction or condition, including:

Serious Condition Potential Symptoms
Allergic Reaction Swelling of the face, tongue, or throat; severe dizziness; difficulty breathing.
Severe Skin Reaction Redness, blistering, or peeling of the skin (including inside the mouth); fever; flu-like symptoms.
Clostridioides difficile (C. diff)-Associated Diarrhea Severe, persistent, or bloody diarrhea; abdominal cramps.
Intracranial Hypertension (Increased pressure around the brain) Severe headache that doesn't go away; blurred or double vision; vision loss.
Esophageal Irritation/Ulceration Difficulty or pain when swallowing; pain or burning in the throat or chest.

Important Safety Information

Vibratab may cause permanent tooth discoloration (yellow-gray-brown) if taken during tooth development, which is typically in children under 8 years of age. Therefore, its use in this age group is generally avoided. Taking the medication with plenty of fluid while standing or sitting upright can help reduce the risk of esophageal irritation. Consult your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Vibratab

Element Official Regulatory Statement/Entity
Documented overdose presentations Over-exposure primarily results in an increased incidence of known adverse effects, including gastrointestinal symptoms (nausea, vomiting, diarrhea) and significant photosensitivity.
Physiological systems affected (as stated in label) CNS (e.g., intracranial hypertension or pseudotumor cerebri in adults); Hepatic (potential liver injury); and Renal (dose-related rise in BUN) are documented as systems where high systemic levels pose a risk.
Dose-related or exposure-related factors (if applicable) Excessive systemic accumulation is associated with increased toxicity, with underlying renal impairment noted as a factor that can increase the risk of severe outcomes.
Population-specific overdose notes (if applicable) In infants, high systemic levels may cause bulging fontanels, a manifestation of increased intracranial pressure.
Emergency-response statements (as written in official documents) Call the poison control helpline for guidance on a suspected over-exposure.
When immediate medical help is required (label-derived phrasing only) Immediately call emergency services (e.g., 911) if the individual has collapsed, experienced a seizure, has trouble breathing, or can't be awakened.

Overdose Classifications (High-Level)

Element Official Regulatory Statement/Entity
Severity classification (as defined in official documents) Symptoms are documented to range from increased adverse effects to life-threatening outcomes requiring immediate intervention.
Regulatory basis (EMA / FDA / etc.) Information derived from FDA Labeling, DailyMed (NIH), and MedlinePlus (NIH).
Overdose-context constraints (as defined in official documents) Management is restricted to supportive measures as no specific antidote is known.

Resulting Overdose Structure

Official overdose statements: • The primary manifestation of overdose is an increased incidence of known adverse effects, particularly gastrointestinal and dermatological issues. • Intracranial hypertension in adults and liver injury represent documented severe risks of excessive systemic accumulation. • Treatment is symptomatic and supportive, and no specific antidote is known. • Regulatory guidance mandates calling emergency services immediately for severe manifestations such as collapse, seizure, or difficulty breathing.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Doxycycline overdose profile as an exacerbation of known toxicities that may affect the CNS, liver, and kidneys at high concentrations. This definition establishes the critical need to seek immediate medical attention for the onset of specific, severe manifestations like seizure or collapse, while officially confining treatment to symptomatic and supportive measures.

Therapeutic Uses of Vibratab

Vibratab (Doxycycline) is relevant for easing certain distressing symptoms by addressing symptoms related to systemic imbalance and inflammatory or irritative states. Its uses are applicable across domains of infectious disease, chronic inflammation, and prophylaxis.

The medicine is relevant in conditions characterized by periods of heightened symptoms, including Rickettsial fevers, specific respiratory, urinary tract, and sexually transmitted infections, as well as moderate to severe acne and papulopustular rosacea. It is applied in clinical settings that involve acute or disruptive symptom patterns, and is often used during phases when symptoms become more noticeable.

“This application provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.”

Vibratab plays a role in managing symptom clusters that may become intense or disruptive, such as fever, localized inflammation, papules, and malaise. In addition to therapeutic use, it is considered relevant for prevention, including malaria prophylaxis for travelers and post-exposure protection against serious pathogens like Anthrax and certain symptoms associated with Lyme disease. This supportive relief assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Inflammatory Symptoms Domain Benefit Focus
Infectious Disease Easing systemic malaise and fever.
Dermatology Reducing papules and facial redness.
Prophylaxis Supports prevention of acute symptoms.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Vibratab — Official Regulatory Information

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults and pediatric patients 8 years of age and older.
Populations for whom use is not recommended (if applicable) Breastfeeding women and children aged 8 to 12 years (for certain non-life-threatening uses).
Populations for whom use is contraindicated Persons with known hypersensitivity to doxycycline or any other tetracycline-class antibiotics.
Women during the last half of pregnancy (second and third trimesters).

Age-Related and Condition-Specific Eligibility

  • Children under 8 years old: General use is contraindicated or not recommended due to the risk of permanent tooth discoloration and inhibition of bone growth. Use is conditionally permitted only for certain severe or life-threatening infections, such as Anthrax or Rocky Mountain Spotted Fever, when alternative therapies are unavailable.
  • Impaired Hepatic Function: Use requires caution in patients with liver impairment, and it may be contraindicated in cases of severe disturbance of liver function.
  • Impaired Renal Function: Unlike some other tetracyclines, the official labeling states that no dose reduction is typically required for patients with impaired kidney function.

Pregnancy and Lactation Eligibility Status

Use during the last half of pregnancy is contraindicated due to the risk of fetal harm to developing teeth and bone. Use is not recommended in lactating women, as the medicine is excreted into human milk.


The regulatory eligibility profile is strictly defined by absolute contraindications related to allergic history and the tetracycline class risk to developing teeth and bone in young children and fetuses. All other uses are permitted for adults and older children, with specific caution advised for patients with existing liver conditions or risk factors for intracranial hypertension.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Vibratab (Doxycycline) as defined by government regulatory authorities.


Documented High-Risk Combinations

The co-administration of Vibratab with certain medicines is formally restricted due to the potential for serious outcomes:

  • Isotretinoin: Concomitant use must be avoided due to the increased risk of benign intracranial hypertension (pseudotumor cerebri).
  • Methoxyflurane: Concurrent use has been reported to result in fatal renal toxicity.

Alteration of Drug Exposure

Several substances are documented to affect the concentration or clearance of Doxycycline, requiring appropriate management to prevent reduced exposure:

Interaction Type Interacting Agents (Examples)
Reduced Absorption Antacids, Iron-containing Preparations, Bismuth Subsalicylate
Decreased Half-Life Phenytoin, Carbamazepine, Barbiturates

Administration of agents that impair absorption must be separated from Vibratab. Conversely, drugs that decrease Doxycycline's half-life may lead to reduced systemic levels.

Pharmacodynamic Effects

Vibratab may also alter the activity of other medicines:

  • Oral Contraceptives: Tetracycline-class drugs may render these products less effective.
  • Anticoagulants: Doxycycline has been reported to depress plasma prothrombin activity, meaning dosage adjustment of the anticoagulant may be required.
  • Penicillin: Regulatory advice suggests avoiding co-administration to prevent interference with Penicillin's bactericidal action.

Mechanism of Action

Vibratab's action is governed by two distinct mechanistic domains: targeting microbial protein production and modulating host tissue-degrading enzymes, which together influence the molecule's physiological profile.


Blocking Microbial Growth Machinery

This domain involves the molecule's primary action as a non-competitive inhibitor of the 30S prokaryotic ribosomal subunit . By binding to this vital structure, the molecule blocks the addition of new amino acids to the polypeptide chain, which arrests the microbe's ability to synthesize essential proteins for growth. This action suppresses microbial proliferation, influencing the density of susceptible organism populations.


Modulating Host Tissue-Damaging Enzymes

Independently of its effect on microorganisms, the molecule also engages a secondary mechanism by inhibiting a family of host enzymes called Matrix Metalloproteinases (MMPs) . These enzymes are responsible for breaking down the body's structural matrix during inflammatory processes. By suppressing MMP activity, the drug limits excessive tissue degradation and influences the structural integrity of the local environment, which exerts an anti-inflammatory action and modulates structural matrix integrity.

Dosage and Administration Information

Vibratab (Doxycycline) is primarily administered via the oral route using immediate-release or delayed-release tablets or capsules, with an intravenous infusion available as an approved alternative when oral intake is not feasible. The standard adult regimen for many conditions begins with a loading phase of 200 mg on the first day, typically administered as 100 mg taken every 12 hours. This is followed by a maintenance dose, usually 100 mg once daily. For more severe infections, the maintenance dose may be increased to 100 mg taken every 12 hours throughout the course of treatment.

Treatment duration varies significantly based on the condition being managed, spanning from courses of seven days for uncomplicated infections to sustained 60-day regimens for certain types of prophylaxis. Special constraints govern oral administration: doses must be swallowed with an adequate amount of fluid (such as 100 ml of water), and the patient is directed to remain upright for at least 30 minutes following intake. Administration near bedtime should be avoided. While standard formulations may be taken with food to aid tolerance, delayed-release forms must be taken on an empty stomach and must not be crushed, broken, or opened.

Dosage modifications are required for pediatric patients (aged 8 years and older weighing less than 45 kg), where dosing is calculated based on body weight. No dose adjustment is specified for older adults or in the presence of renal impairment. If a dose is missed, it should be taken as soon as remembered, but patients must not double the dose to compensate for the missed amount.

Recent Clinical Evidence

Research evidence / Overview of studies for Vibratab

This overview summarizes the type of research that has been conducted on Doxycycline (Vibratab) for its approved uses, detailing what was studied, what findings were described in the research, and what remains uncertain. This information is based on official documents from regulatory bodies and peer-reviewed scientific literature.


Evidence for Use in Systemic Anti-Infective and Prophylactic Contexts

Studies on the Management of Acute Rickettsial Infections

Doxycycline was studied for conditions presenting with cycles of stability and flare-ups, such as Rickettsial fevers. Studies monitored outcomes related to systemic or functional imbalance, such as fever resolution. Studies report how symptoms evolved in the observed populations, tracking the time needed for recovery to begin. Research data is limited in the sense that it relies more on observational settings and expert consensus than on large-scale, randomized trials (RCTs).

Studies on Prevention and Prophylaxis

Doxycycline was studied for its role in prevention for two indications: Malaria and Anthrax post-exposure prophylaxis (PEP). For malaria, prophylactic efficacy trials researched the ability to prevent infection in travelers. For Anthrax PEP, research was evaluated through public health guidelines and data extrapolated from animal models. The evidence relies heavily on extrapolation due to the public health context, and the results apply primarily to the populations studied.


Evidence for Use in Sexually Transmitted and Respiratory Infections

Treatment Trials for Specified Sexually Transmitted Infections

Doxycycline was evaluated in Randomized Controlled Trials (RCTs) and systematic reviews for addressing conditions associated with acute or disruptive episodes. These studies examined outcomes such as the rate of organism eradication and the resolution of clinical signs. Research highlights changes measured during the study period against comparison groups. The primary area of uncertainty is the continuous research needed to understand the implications of emerging antimicrobial resistance.

Evidence for Use in Chronic Inflammatory Dermatological Conditions

Doxycycline was studied for conditions characterized by fluctuating or episodic manifestations, particularly severe acne and papulopustular rosacea. These RCTs and maintenance studies explored outcomes linked to inflammatory or irritative states, such as tracking the number of inflammatory papules and pustules. The evidence contributes to the broader evidence landscape; however, studies are ongoing to track long-term outcomes after treatment is stopped, and there is continuous research interest in antimicrobial resistance (AMR) development.

Frequently Asked Questions (FAQ)

Common questions about Vibratab (FAQ)


Q: Is Vibratab the same kind of drug as [Similar Drug Name]?

A: Vibratab contains the active ingredient doxycycline, which is a member of the tetracycline class of antibiotics. This official classification describes the medicine's general method of action against bacteria.

When considering other medicines, regulatory information groups them by these classes to understand similarities in how they work and their overall profile.

Q: Are there common feelings or sensations people get when they first start taking Vibratab?

A: Official drug labels indicate that common initial side effects are often related to the stomach and digestive system, which may include nausea, vomiting, or diarrhea.

Less frequent effects, such as headache or dizziness, have been reported in some patients. These are generally mild and are listed in the drug's safety information.

Q: Is it normal to have a slight headache when starting Vibratab?

A: Headache is documented as a possible side effect of the medicine. Official safety information helps distinguish between minor reported effects and potential signs of a more serious condition.

Warnings state that a severe, persistent headache combined with visual changes, like blurred or double vision, could be a sign of a rare but serious condition called intracranial hypertension.

Q: Is Vibratab generally considered safe for long-term use?

A: Regulatory approvals allow for the use of this medicine in treatment courses ranging from short periods to sustained 60-day regimens for certain specific indications.

Beyond this, the overall long-term safety profile is continually monitored by regulatory bodies through ongoing post-marketing surveillance.

Q: Can I take other vitamins or supplements while using Vibratab?

A: Official safety documents advise caution with supplements that contain high levels of certain minerals. Preparations containing iron, calcium, magnesium, or zinc should be avoided around the time of your dose.

These minerals can interfere with the body's absorption of the medicine, potentially making it less effective. The drug label suggests a separation period between the intake of these minerals and the medication to help maintain effectiveness.

Q: Why are there different strengths of Vibratab available?

A: The various available strengths, such as 50 mg, 100 mg, 200 mg and 40 mg formulations, are provided to allow for flexible dosing.

This is necessary because different medical conditions require different amounts of the medicine, such as a high initial loading dose for an acute infection versus a lower daily maintenance dose for a chronic skin condition.

Q: What common over-the-counter cold medicines might interact with Vibratab?

A: Regulatory safety information warns that common over-the-counter products, especially for colds, may contain interacting ingredients.

Specifically, medicines with antacids, iron-containing preparations, or bismuth subsalicylate can reduce the absorption of Vibratab. Separation of the intake of these products from the medication dose by several hours is typically suggested to minimize interaction risk.

Q: What kind of improvement should I generally expect to see with Vibratab?

A: Studies and clinical trials demonstrate that for approved infections, the medicine is expected to lead to the eradication of the targeted organism and the resolution of clinical signs, such as fever or inflammatory lesions.

The specific time frame for seeing improvement is highly variable and depends on the condition being treated.

Q: Are there common mental side effects associated with Vibratab?

A: Official safety information primarily lists common physical effects, mainly affecting the digestive system. However, less frequent side effects such as dizziness have also been reported.

The serious, rare neurological symptoms like severe headache are linked to intracranial hypertension, not common changes in mood or mental state.

Q: What is the official definition of 'Contraindications' related to Vibratab?

A: A contraindication is an official statement in regulatory documents that specifies a condition or factor which makes taking the drug generally inappropriate.

For Vibratab, the main contraindications defined by official bodies include a known allergy to any tetracycline medicine and use during the last half of pregnancy.

Q: What evidence exists about Vibratab's effectiveness in real-world use?

A: Evidence of the drug's effectiveness is drawn from a variety of sources, including tightly controlled clinical trials and systematic reviews.

For certain conditions, effectiveness is also evaluated through observational settings and public health data, which provide broader context on how the medicine performs outside of strictly controlled research.

Q: Is there a possibility of becoming tolerant to the effects of Vibratab over time?

A: Official regulatory and scientific documents focus on the important concern of antimicrobial resistance (AMR). This concept involves bacteria adapting and potentially becoming unaffected by the medicine, which is why it remains a topic of scientific interest.

AMR is a subject of continuous monitoring and research interest by regulatory bodies.

Q: How quickly does Vibratab usually start to work?

A: According to pharmacokinetic studies, the drug is rapidly and almost completely absorbed after a dose is taken orally.

Peak levels in the bloodstream, known as Cmax, are typically reached in approximately 1.5 to 3.0 hours.

Q: How long does the effect of Vibratab typically last?

A: Official pharmacokinetic data shows that the medicine is eliminated from the body with a half-life of approximately 18 hours.

This means it takes about 18 hours for half of the dose to be cleared from the system. This longer half-life supports the use of once- or twice-daily dosing schedules.

Q: Why do some people say they feel sleepy or tired after taking Vibratab?

A: Tiredness or fatigue is generally not listed as a common, direct side effect of this medicine in official documents.

However, fatigue can sometimes be a general symptom of the underlying infection being treated, or it could be related to common side effects like gastrointestinal upset or increased sensitivity to the sun.

Q: Does Vibratab interact with common pain relievers like ibuprofen?

A: Official drug labels do not specifically list ibuprofen (a type of pain reliever) as a recognized interaction that changes the effectiveness of the drug.

Regulatory warnings mention the need for care when this medicine is taken alongside other agents known to cause irritation to the stomach or esophagus.

Q: Is there a list of foods or drinks to avoid while using Vibratab?

A: Regulatory documents highlight that products high in certain minerals should be avoided at the time of your dose. The key substances are calcium, iron, magnesium, or aluminum, which are found in many dairy products, certain juices, and mineral supplements.

Official advice emphasizes taking the dose with an adequate amount of fluid to assist administration.

Q: How does Vibratab compare to older treatments for the same condition, in general terms?

A: Vibratab is officially classified as a semi-synthetic derivative that was developed later than the first-generation tetracyclines.

Official information describes it as having characteristics like a longer half-life and a different binding profile compared to some of the original drugs in its class.

Q: What does the patient information leaflet say about alcohol consumption with Vibratab?

A: Official patient information does not typically provide broad, definitive guidance on moderate alcohol consumption for every patient.

Regulatory warnings indicate that special consideration may be necessary for patients with a history of liver issues or alcohol dependence, given that the drug is processed by the liver.

Q: Why did my doctor prescribe me Vibratab instead of another option?

A: Vibratab is officially described as a broad-spectrum anti-infective agent used to treat a wide array of diseases caused by susceptible organisms.

A healthcare professional may select this medicine because it is known to be effective against the specific type of infection a patient has, or when other common antibiotics are contraindicated.

Q: What is the reason Vibratab is sometimes described as 'non-addictive'?

A: Doxycycline, the active ingredient, is officially not classified as a controlled substance by major regulatory bodies like the U.S. DEA.

It is a prescription antibiotic with no known potential for abuse or dependence, which means it does not fall under regulations governing habit-forming drugs.

Q: How does the way Vibratab works differ from other drugs in its class?

A: Official documentation highlights that this medicine has a dual mechanism of action, which makes it distinct.

In addition to its primary antibiotic function of suppressing bacterial growth, it also acts independently by modulating host tissue-damaging enzymes (MMPs) within the body.

Q: Is there a generic version of Vibratab available yet?

A: Yes, the active ingredient in Vibratab, doxycycline hyclate, is available in generic versions that have been approved by regulatory bodies like the FDA.

These generics are available in various forms and strengths, providing alternatives to the brand-name product.

Q: Can you feel better immediately after taking Vibratab, or is it a gradual change?

A: Studies show the medicine is rapidly absorbed, and you may begin to feel slight symptom resolution within a few hours. However, the medicine works by gradually stopping the bacteria from multiplying, so full clinical improvement is a gradual process.

Official information supports the importance of completing the full prescribed course to achieve the best clinical outcome.

Q: What happens if I stop taking Vibratab suddenly?

A: Official patient advice stresses the importance of completing the full prescribed course of treatment.

Stopping the medicine too early, even if you feel better, can lead to treatment failure and allows the remaining bacteria to potentially regrow. This action may also contribute to the development of antimicrobial resistance.

Q: Is it true that you can't drive or operate machinery while taking Vibratab?

A: The drug's official label advises caution regarding activities requiring full alertness. Side effects such as dizziness, visual disturbances (blurred or double vision), or headache have been reported.

If these specific effects appear, patients are advised to refrain from driving or operating complex machinery.

Q: Are there any known issues with taking Vibratab and getting certain lab tests?

A: Regulatory documents note that the drug has been reported to interfere with certain clinical tests.

Specifically, it can cause false elevations of urinary catecholamine levels when a specific fluorescence test is performed, which could potentially lead to inaccurate test results.

Q: Does Vibratab require special monitoring from a healthcare provider?

A: In most cases, standard clinical monitoring is used during treatment. However, official information states that if a patient has impaired kidney or liver function, or if the therapy is prolonged, special monitoring may be needed to prevent potential accumulation of the medicine.

Q: Are there any restrictions on donating blood while taking Vibratab?

A: General guidelines from blood donation centers indicate that donation is usually acceptable if the medicine is being used for a chronic, preventative, or mild condition like acne.

However, if the medicine is being taken to treat an active systemic infection, donation is generally deferred until the infection has cleared.

Q: Can taking Vibratab affect sleep patterns?

A: The medicine is generally not reported to cause common side effects that directly alter sleep patterns.

However, official administration instructions advise that the dose near bedtime should be avoided to minimize the risk of irritation or ulceration of the esophagus, which could indirectly lead to a disrupted sleep.

How should Vibratab be stored and disposed of?

Storage and Disposal of Vibra-Tabs (Doxycycline Hyclate)

Vibra-Tabs must be stored according to regulatory requirements to ensure stability and effectiveness.

Storage Conditions

Requirement Official Specification
Temperature Controlled Room Temperature: 20^circ to 25 C (68^circ to 77 F).
Protection Must be protected from light and moisture and kept away from excess heat.
Container Store in a tight, light-resistant container with a child-resistant closure.

Disposal and Safety

The medication must be kept out of the reach of children.

Expired product must be properly discarded following federal, state, and local disposal regulations. Outdated tetracycline-related drugs may result in serious illness, mandating disposal after the expiration date. Do not flush the medication down the toilet or pour it into a drain unless instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vibratab found in:

A-Z Index: